Mindray's $927M Vertical Integration Play
Medical device giant Mindray is moving aggressively into vertical integration, announcing a $927 million deal to acquire control of APT Medical. The deal significantly strengthens Mindray’s capabilities in advanced medical equipment, positioning it to compete more directly with Siemens and GE HealthCare through bundled, workflow-integrated imaging solutions.
The deal gives Mindray a controlling 24.61% stake in APT Medical through a combination of direct share transfers and a waiver of voting rights by some existing shareholders. The purchase price of CNY 471.12 per share marked a 30.67% premium over APT's closing price on January 26, 2024, valuing the entire company at $4.26 billion. This acquisition catapults Mindray into the rapidly expanding cardiovascular device market, a sector valued at $56 billion globally and nearly $7 billion in China alone. APT Medical is a domestic Chinese leader in electrophysiology catheters and vascular intervention devices for coronary and peripheral diseases, product lines that Mindray previously lacked. A key synergy is leveraging Mindray's global sales network, which spans over 50 subsidiaries outside of China. This is a critical growth lever for APT Medical, which generated only a modest 11% of its revenue from international markets in 2022. The move is playing out against a seismic shift in imaging site-of-care, as payers like Cigna and UnitedHealthcare implement policies that push non-emergency CT and MRI procedures away from hospitals toward lower-cost freestanding centers. This industry-wide migration is driving double-digit
